These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17990370)

  • 1. Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.
    Boyle BA; Elion R; Cohen CJ; DeJesus E; Hawkins T; Moyle GJ
    AIDS Read; 2007 Oct; 17(10):484-90. PubMed ID: 17990370
    [No Abstract]   [Full Text] [Related]  

  • 2. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 3. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity.
    Albrecht H
    AIDS Clin Care; 2007 Oct; 19(10):81-2. PubMed ID: 18398994
    [No Abstract]   [Full Text] [Related]  

  • 4. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 6. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 7. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
    Bartnof HS
    BETA; 1998 Apr; ():49-56. PubMed ID: 11365269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
    Frissen PH; de Vries J; Weigel HM; Brinkman K
    AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary report on 1592.
    AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 11. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
    Linde M
    Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759
    [No Abstract]   [Full Text] [Related]  

  • 12. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 13. Anaphylaxis after rechallenge with abacavir.
    Walensky RP; Goldberg JH; Daily JP
    AIDS; 1999 May; 13(8):999-1000. PubMed ID: 10371187
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
    [No Abstract]   [Full Text] [Related]  

  • 15. Scientists find some genes a bad omen for anti-HIV drug.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
    Brothers C; Cutrell A; Scott T; Hernandez J; Moult A
    Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867
    [No Abstract]   [Full Text] [Related]  

  • 17. The abacavir hypersensitivity reaction and interruptions in therapy.
    Loeliger AE; Steel H; McGuirk S; Powell WS; Hetherington SV
    AIDS; 2001 Jul; 15(10):1325-6. PubMed ID: 11426085
    [No Abstract]   [Full Text] [Related]  

  • 18. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.